At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- UCB5285 (drug), Placebo (other)
- How long the study runs
- Study runs about 12 months (dates as stated)
- About the drug or intervention
- UCB5285 — drug: Participants will receive UCB5285 as prespecified in each cohort. · Placebo — other: Participants will receive matching placebo as prespecified in each cohort.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years to 55 Years
- Who
- All
- Number of participants
- 80
- Started
- 2025-12-08
- Last checked
- 2026-07
Plain English Summary
What is this study?
- • Testing a new treatment for healthy participants
- • Phase1 - 80 participants
- • The purpose of this study is to evaluate the safety and tolerability of single ascending doses of UCB5285 in healthy study participants, including healthy Japanese study participants
Who can take part?
- • Ages 18 Years to 55 Years
- • Diagnosed with healthy participants
Where?
- • Harrow - Up0161 1001
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to evaluate the safety and tolerability of single ascending doses of UCB5285 in healthy study participants, including healthy Japanese study participants
Healthy Participants
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 55 Years
- Who can join: All genders
What the study is looking for
- ✓For all study participants:
- ✓Study participant must be 18 to 55 years of age, inclusive, at the time of signing the agreement to take part
- ✓Study participants who are overtly healthy as determined by medical evaluation including medical history, physical...
- ✓Body weight within 40 kilograms (kg) to 110 kg and body mass index (BMI) within the range of 18 kilograms per meter...
Who cannot take part
- ✗Study participant has a recent history (within 6 months of Screening) or currently active clinically significant...
- ✗Study participant has a significant allergy to humanized monoclonal antibody (mAbs)
See the full criteria
Inclusion Criteria:
* For study participants of Japanese origin: study participant who is born in Japan and of Japanese descent as evidenced in appearance and verbal confirmation of familial heritage with all 4 grandparents and both parents born in Japan and has not had a significant change in lifestyle or diet since leaving Japan
* For all study participants:
* Study participant must be 18 to 55 years of age, inclusive, at the time of signing the informed consent
* Study participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
* Body weight within 40 kilograms (kg) to 110 kg and body mass index (BMI) within the range of 18 kilograms per meter square (kg/m2) to 30 kg/m2 (inclusive)
Exclusion Criteria:
* Study participant has a history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, electrocardiogram (ECG), or vital sign that, in the opinion of the investigator, could significantly alter the absorption, or elimination of drugs; constitute a risk when taking the study intervention; or interfere with the interpretation of data
* Study participant has a recent history (within 6 months of Screening) or currently active clinically significant bacterial, fungal, endoparasite, or viral infection.
* Study participant has a significant allergy to humanized monoclonal antibody (mAbs)
Where Is This Study? (1 UK site)
Up0161 1001
Harrow, United Kingdom
Data sourced from ClinicalTrials.gov · Last verified: 2026-07
